Medicilon Logo
|
search icon search icon language icon contact icon menu icon
Medicilon Logo
|
search icon close search icon language icon contact icon menu icon
logo icon CN
Contact Us
Close Button
Message
Back To Top
Online Message×
Click switch
Close Button
Medicilon Events
News and Events

Medicilon Events

Hot information:
Two Innovative Service Platforms of Medicilon were Selected as Shanghai International Service Trade Demonstration project| Medicilon and Wuhan biolake successfully organized a biopharmaceutical salon| Medicilon FTE/FFS services - flexible and efficient cooperation model
Apr 27,2022
Medicilon was selected as a constituent stocks of the STAR 50 Index
On February 25, the Shanghai Stock Exchange announced that they decided to adjust the sample of the STAR 50 Index, which will take effect after the market closes on March 11, 2022.
More
Medicilon was selected as a constituent stocks of the STAR 50 Index
Apr 19,2022
Lockdown But Not Stop - Medicilon Researchers Continue to Fight
Medicilon is deeply aware of its responsibilities toemployees, pharmaceutical companies and scientific research institutions, and even for the entire biopharmaceutical industry chain as an integrated prclinial R&D facility.
More
Lockdown But Not Stop - Medicilon Researchers Continue to Fight
Apr 19,2022
Medicilon Appoints Dr. Christopher Stewart, DABT as Senior Scientific Advisor
Shanghai Medicilon Inc. announced the appointment of Dr. Christopher Stewart, DABT as the Senior Scientific Advisor of Medicilon.
More
Medicilon Appoints Dr. Christopher Stewart, DABT as Senior Scientific Advisor
Mar 14,2022
Medicilon assisted China's First Original Research Highly Selective EP4 Receptor Antagonist YY001 Obtained Clinical Approval
Shanghai Medicilon Inc. (Medicilon) provided GLP-compliant toxicology DRF tests and application materials for the research and development of YY001, which accelerating the project to get into Phase 1 clinical trials.
More
Medicilon assisted China's First Original Research Highly Selective EP4 Receptor Antagonist YY001 Obtained Clinical Approval
Mar 02,2022
Focus on Universal CAR-NK Cell Therapy! Medicilon's Partner Imbioray Completes 230 million Round A Financing
On February 22, Shanghai Medicilon Inc (Medicilon)'s partner Imbioray (Hangzhou) Biomedicine Co., Ltd. (Imbioray) announced the completion of RMB 230 million Round A financing.
More
Focus on Universal CAR-NK Cell Therapy! Medicilon's Partner Imbioray Completes 230 million Round A Financing
Feb 28,2022
Medicilon Won Praise and Awards From Many Partners
Leading Tac Pharma's PROTAC drug project is a first-in-class research and development project that challenges anti-tumor and autoimmune diseases. In the cooperation with Medicilon, the Medicilon's DMPK team actively communicated with Leading Tac which helped customers solve a series of research and development problems such as large molecular weight, ensuring the completion of the project.
More
Medicilon Won Praise and Awards From Many Partners
Feb 18,2022
Medicilon Appoints Dr. Zhenrong Guo as Executive Vice President of VCMC
Recently, Shanghai Medicilon Inc. (stock code: 688202.SH) (Medicilon) announced the appointment of Dr. Zhenrong Guo as the Executive Vice President of VCMC(APIs + Preparations).
More
Medicilon Appoints Dr. Zhenrong Guo as Executive Vice President of VCMC
Feb 17,2022
World's First Inhaled Nanobody Drug LQ036
In the development process of the world's first inhaled nanobody drug for the treatment of moderate and severe asthma, Medicilon assists LQ036 to complete the quality research services of inhaled preparations.
More
World's First Inhaled Nanobody Drug LQ036
Jan 27,2022
Happy Chinese New Year!
Happy Chinese New Year!
More
Happy Chinese New Year!
Jan 24,2022
Medicilon Assisted DAC Biotechnology's Fourth ADC Drug DXC007 Getting Approved for Clinical Use
On December 28, 2021, Hangzhou DAC Biotechnology Co., Ltd. (DAC Biotech) DXC007 project was successfully approved for clinical trials. DXC007 is the fourth ADC drug approved for clinical use by DAC Biotech, and it is also the fourth ADC drug that Shanghai Medicilon Inc. (Medicilon) to help DAC Biotech successfully getting approval.
More
Medicilon Assisted DAC Biotechnology's Fourth ADC Drug DXC007 Getting Approved for Clinical Use
Jan 11,2022
Medicilon Assisted Regor Therapeutics Group's New-generation Tumor-targeting Inhibitor RGT-419B Getting Approved for Clinical Use
On December 28, 2021, the new generation of CDK2/4/6 small molecule inhibitor RGT-419B independently developed by Regor Therapeutics Group (Regor) was approved by the U.S. Food and Drug Administration (FDA).
More
Medicilon Assisted Regor Therapeutics Group's New-generation Tumor-targeting Inhibitor RGT-419B Getting Approved for Clinical Use
Jan 10,2022
Bao Pharmaceutical and Medicilon reached a strategic collaboration
On December 17, 2021, Shanghai Bao Pharmaceutical Co., Ltd. (Bao) and Shanghai Medicilon Inc. (Medicilon) signed an innovative drug IND R&D service strategy collaboration agreement.
More
Bao Pharmaceutical and Medicilon reached a strategic collaboration